Aura Biosciences, Inc. (AURA)
6.56
+0.27
(+4.29%)
USD |
NASDAQ |
Oct 20, 16:00
6.565
0.00 (0.00%)
After-Hours: 20:00
Aura Biosciences Enterprise Value : 371.58M for Oct. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 20, 2026 | 371.58M |
| October 19, 2026 | 343.64M |
| October 16, 2026 | 323.98M |
| October 15, 2026 | 348.82M |
| October 14, 2026 | 331.23M |
| October 13, 2026 | 341.57M |
| October 12, 2026 | 369.51M |
| October 09, 2026 | 369.51M |
| October 08, 2026 | 365.89M |
| October 07, 2026 | 361.24M |
| October 06, 2026 | 331.23M |
| October 05, 2026 | 336.40M |
| October 02, 2026 | 322.95M |
| October 01, 2026 | 317.77M |
| September 30, 2026 | 342.61M |
| September 29, 2026 | 329.16M |
| September 28, 2026 | 329.16M |
| September 25, 2026 | 313.63M |
| September 24, 2026 | 329.16M |
| September 23, 2026 | 315.70M |
| September 22, 2026 | 360.20M |
| September 21, 2026 | 350.89M |
| September 18, 2026 | 359.17M |
| September 17, 2026 | 374.69M |
| September 16, 2026 | 389.18M |
| Date | Value |
|---|---|
| September 15, 2026 | 408.84M |
| September 14, 2026 | 418.15M |
| September 11, 2026 | 416.60M |
| September 10, 2026 | 416.08M |
| September 09, 2026 | 437.81M |
| September 08, 2026 | 454.37M |
| September 04, 2026 | 475.06M |
| September 03, 2026 | 455.40M |
| September 02, 2026 | 468.85M |
| September 01, 2026 | 461.61M |
| August 31, 2026 | 435.74M |
| August 28, 2026 | 458.51M |
| August 27, 2026 | 489.55M |
| August 26, 2026 | 492.66M |
| August 25, 2026 | 501.97M |
| August 24, 2026 | 510.25M |
| August 21, 2026 | 499.90M |
| August 20, 2026 | 496.79M |
| August 19, 2026 | 498.86M |
| August 18, 2026 | 537.15M |
| August 17, 2026 | 487.48M |
| August 14, 2026 | 488.52M |
| August 13, 2026 | 484.38M |
| August 12, 2026 | 494.72M |
| August 11, 2026 | 524.73M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.090B |
| Oncolytics Biotech, Inc. | 58.48M |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 2.282B |
| Anixa Biosciences, Inc. | 77.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -45.64M |
| Total Expenses (Quarterly) | 45.64M |
| EPS Diluted (Quarterly) | -0.4811 |
| Earnings Yield | -27.11% |
| Normalized Earnings Yield | -27.11 |